EVAX Quote, Financials, Valuation and Earnings

Ascendis Pharma A/S has a net margin of -64.14% compared to Evaxion AS's net margin of -28.55%. Evaxion AS's return on equity of -- beat Ascendis Pharma A/S's return on equity of -880.05%.

Evaxion AS has a consensus price target of $14.19, signalling upside risk potential of 346.15%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $278.54 which suggests that it could grow by 23.7%. Given that Evaxion AS has higher upside potential than Ascendis Pharma A/S, analysts believe Evaxion AS is more attractive than Ascendis Pharma A/S.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.4%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are $37.5K, which are smaller than Ascendis Pharma A/S quarterly revenues of $249.6M. Evaxion AS's net income of -$4.9M is higher than Ascendis Pharma A/S's net income of -$71.3M. Notably, Evaxion AS's price-to-earnings ratio is -- while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 2.13x versus 18.91x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -64.14% compared to Evaxion AS's net margin of 1.68%. Evaxion AS's return on equity of -- beat Cellectis SA's return on equity of -31.08%.

Evaxion AS has a consensus price target of $14.19, signalling upside risk potential of 346.15%. On the other hand Cellectis SA has an analysts' consensus of $7.00 which suggests that it could grow by 84.7%. Given that Evaxion AS has higher upside potential than Cellectis SA, analysts believe Evaxion AS is more attractive than Cellectis SA.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.823, suggesting its more volatile than the S&P 500 by 182.278%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are $37.5K, which are smaller than Cellectis SA quarterly revenues of $35M. Evaxion AS's net income of -$4.9M is lower than Cellectis SA's net income of $586.4K. Notably, Evaxion AS's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 2.13x versus 4.71x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -64.14% compared to Evaxion AS's net margin of --. Evaxion AS's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.

Evaxion AS has a consensus price target of $14.19, signalling upside risk potential of 346.15%. On the other hand DBV Technologies SA has an analysts' consensus of $39.69 which suggests that it could grow by 83.37%. Given that Evaxion AS has higher upside potential than DBV Technologies SA, analysts believe Evaxion AS is more attractive than DBV Technologies SA.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are $37.5K, which are larger than DBV Technologies SA quarterly revenues of --. Evaxion AS's net income of -$4.9M is higher than DBV Technologies SA's net income of -$33M. Notably, Evaxion AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 2.13x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of -64.14% compared to Evaxion AS's net margin of 26.68%. Evaxion AS's return on equity of -- beat Novo Nordisk A/S's return on equity of 68.76%.

Evaxion AS has a consensus price target of $14.19, signalling upside risk potential of 346.15%. On the other hand Novo Nordisk A/S has an analysts' consensus of $59.51 which suggests that it could grow by 0.13%. Given that Evaxion AS has higher upside potential than Novo Nordisk A/S, analysts believe Evaxion AS is more attractive than Novo Nordisk A/S.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.529%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 2.91% to investors and pays a quarterly dividend of $0.58 per share. Evaxion AS pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evaxion AS quarterly revenues are $37.5K, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Evaxion AS's net income of -$4.9M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Evaxion AS's price-to-earnings ratio is -- while Novo Nordisk A/S's PE ratio is 17.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 2.13x versus 5.67x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.